Injectafer is owned by Am Regent.
Injectafer contains Ferric Carboxymaltose.
Injectafer has a total of 9 drug patents out of which 0 drug patents have expired.
Injectafer was authorised for market use on 25 July, 2013.
Injectafer is available in solution;intravenous dosage forms.
Injectafer can be used as method to treat ida in adults with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder weighing at least 40 kg by administering iv ferric carboxymaltose to give at least 0.6 g of iron in 15 minutes or less; method to treat iron deficiency anemia in adults with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0.6 g of elemental iron in 15 minutes or less; method to treat iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least 0.6 g of elemental iron in 15 minutes or less, a method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron; a method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron; method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron; method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron, method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g of elemental iron in 15 minutes; method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g of elemental iron in less than 15 minutes; method to treat ida in adults & pediatric patients 1 year & older with intolerance or unsatisfactory response to oral iron & heavy uterine bleeding or gi disorder by administering iv ferric carboxymaltose to give at least 0.7 g of iron in 15 minutes; method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 46.7 kg by administering iv ferric carboxymaltose to provide at least 0.7 g of elemental iron in < 15 minutes, method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex; method of treating iron deficiency anemia in adults who have intolerance to or have had unsatisfactory response to oral iron associated with heavy uterine bleeding or a gastrointestinal disorder by intravenously administering ferric carboxymaltose; a method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron; a method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron; method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron; method of treating ida in adults & pediatric patients 1 yr & older having intolerance or unsatisfactory response to oral iron associated with heavy uterine bleeding or gastrointestinal disorder by intravenously administering ferric carboxymaltose; method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron, method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 grams of elemental iron; method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6 g of elemental iron, method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex, with a substantially non-immunogenic carbohydrate component, in about 15 minutes or less.; method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by administering iv at least about 0.6 g of iron as ferric carboxymaltose in about 15 min or less; method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering at least about 0.6 grams of iron as ferric carboxymaltose in about 15 minutes or less, method of treating iron deficiency anemia in adult patients with non-dialysis dependent chronic kidney disease by intravenously administering ferric carboxymaltose; method to treat iron deficiency anemia in adults & pediatric patients 1 year and older with intolerance or unsatisfactory response to oral iron by intravenously administering ferric carboxymaltose.
The generics of Injectafer are possible to be released after 15 February, 2028.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11291645 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
US11590097 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
US11123321 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
US9376505 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
US7612109 | AM REGENT | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
Feb, 2024
(7 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11433091 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Apr 28, 2024 |
New Patient Population (NPP) | Nov 19, 2024 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g o...
Dosage: SOLUTION;INTRAVENOUS
24
United States
6
European Union
5
Korea, Republic of
3
Canada
3
Hong Kong
3
Denmark
3
Spain
3
Portugal
3
Cyprus
2
Slovenia
2
Brazil
2
China
2
Germany
2
Japan
2
Australia
2
Norway
2
Jordan
1
Saudi Arabia
1
Peru
1
Poland
1
Taiwan
1
Lithuania
1
Malaysia
1
Argentina
1
Hungary
1
Uruguay
1
Mexico
1
New Zealand
1
South Africa
1
Austria
1
Russia
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic